Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK2 | Q15119 | 8/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | CCNC | P24863 | 1/20 | 0.47 |
| ▸ | CDK8 | P49336 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 3/20 | 0.46 |
| ▸ | RAB9A | P51151 | 3/20 | 0.46 |
| ▸ | MMP3 | P08254 | 1/20 | 0.41 |
| ▸ | MMP10 | P09238 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20249189 | 0.94 | PDK2 (0.47) | PDK2POLBCCNCCDK8MEN1 | |
| SCHEMBL20037616 | 0.83 | POLB (0.52) | PDK2POLBCCNCCDK8MEN1 | |
| SCHEMBL20249280 | 0.82 | NPC1 (0.38) | PDK2MEN1KMT2ANPC1RAB9A | |
| SCHEMBL7843212 | 0.82 | KDM4E (0.61) | PDK2POLBCCNCCDK8MEN1 | |
| SCHEMBL20255478 | 0.81 | POLB (0.52) | PDK2POLBCCNCCDK8MEN1 | |
| SCHEMBL18291208 | 0.81 | MEN1 (0.52) | PDK2POLBCCNCCDK8MEN1 | |
| SCHEMBL13946706 | 0.80 | POLB (0.56) | PDK2POLBCCNCCDK8MEN1 | |
| SCHEMBL12228951 | 0.80 | ALDH1A1 (0.39) | POLBMEN1KMT2ANPC1RAB9A | |
| SCHEMBL20249211 | 0.79 | KDM4E (0.64) | MEN1KMT2AKDM4E | |
| SCHEMBL13589470 | 0.78 | POLB (0.52) | PDK2POLBCCNCCDK8MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180161329-A1 | PYRIDO[3,4-D]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | TEIJIN PHARMA LIMITED (JP) | 2018-06-14 | — | — | US | disclosed |
| US-20180161329-A1 | PYRIDO[3,4-D]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | TEIJIN PHARMA LIMITED (JP) | 2018-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180161329-A1 | PYRIDO[3,4-D]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | CDK4, CDK6, CDK16 | PDK2 115/4885POLB 1145/4885CCNC 62/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.